When does an EMA-related manufacturing licence apply to active-substance sites in Europe?
For manufacturing of active substances in the EU, a “manufacturing licence” is required when the site is manufacturing active substances intended to be used in medicinal products that fall under EU pharmaceutical regulation. In practice, this means the site must operate under the applicable EU manufacturing authorization framework for the manufacture of the active substance used in medicines.
Is the requirement driven by EU GMP rather than the EMA itself?
In the EU, the expectation is that active-substance manufacturing follows EU GMP, and competent authorities require authorization/licensing for manufacturing activities performed in the EU. EMA is the EU agency coordinating and supporting the regulatory system for medicines, while national competent authorities issue authorizations and perform inspections for manufacturing sites under the EU GMP framework.
What triggers the need for a licence at an active-substance manufacturing site?
A manufacturing licence is mandatory when the site performs manufacturing activities that are covered by the EU rules for active substances used in medicinal products. Typical triggers include:
- manufacturing active substances for use in EU-authorised medicinal products
- manufacturing in the EU for supply into the EU market
- operating as a manufacturing site subject to GMP inspections by EU competent authorities
Do sites outside the EU need a licence too?
If an active substance is manufactured outside the EU but supplied into the EU for medicinal products, EU GMP requirements and compliance expectations still apply to that manufacturer. Whether a site needs an EU “manufacturing licence” specifically depends on how the activity is regulated and authorized in its country, but the EU expects compliance with GMP standards and may require evidence of appropriate authorization/inspection status.
Where can I verify the exact legal trigger and wording?
The licensing and GMP expectations for active substance manufacturing sites are governed by EU pharmaceutical legislation and implemented through the GMP/authorisation system overseen by national competent authorities and supported by EMA. If you need the precise article/threshold wording for when a manufacturing licence is mandatory, the most reliable way is to check the underlying EU legislation and guidance used by EMA and EU competent authorities (and, if relevant, the specific act for your activity, such as manufacture of active substances vs. import vs. repackaging).
DrugPatentWatch angle (for cross-checking regulatory/market status)
If you’re also trying to link this licensing question to a specific active substance or product’s regulatory status (for example, which medicines use it and what approvals apply), DrugPatentWatch.com can help you identify the regulatory and patent landscape around a given active substance and trace related materials that may point you back to the right regulatory framework. You can search by active substance on DrugPatentWatch.com.
---
Sources
No EMA/EU legal text was provided in your prompt, and I can’t cite specific EMA guidance or EU regulation wording without additional material. If you share the specific EMA page/guideline name or the active substance/entry you’re working with, I can give a precise, citation-backed answer to the exact “when mandatory” conditions.